메뉴 건너뛰기




Volumn 60, Issue 5, 2015, Pages 777-780

Allergic reactions after egg-free recombinant influenza vaccine: Reports to the US vaccine adverse event reporting system

Author keywords

Allergy; Egg; Hypersensitivity; Influenza; Vaccine

Indexed keywords

EGG PROTEIN; INACTIVATED VACCINE; INFLUENZA VACCINE; RECOMBINANT VACCINE;

EID: 84935432979     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu948     Document Type: Article
Times cited : (21)

References (16)
  • 1
    • 84935479791 scopus 로고    scopus 로고
    • US Food and Drug Administration,January 16,Accessed 4 December 2014
    • US Food and Drug Administration. January 16, 2013 Approval Letter-Flublok. Available at: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm410628.htm. Accessed 4 December 2014.
    • (2013) Approval Letter-Flublok
  • 2
    • 84900546305 scopus 로고    scopus 로고
    • Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices-united states, 2013-2014
    • Accessed 4 December 2014
    • Grohskopf LA, Shay DK, Shimabukuro TT, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 2013; 62(RR-07):1-43. Available at: http:// www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm. Accessed 4 December 2014.
    • (2013) MMWR Recomm Rep , vol.62 , Issue.7 RR , pp. 1-43
    • Grohskopf, L.A.1    Shay, D.K.2    Shimabukuro, T.T.3
  • 3
    • 0038341614 scopus 로고    scopus 로고
    • Surveillance for safety after immunization: Vaccine adverse event reporting system (vaers)-united states, 1991-2001
    • Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003; 52:1-24.
    • (2003) MMWR Surveill Summ , vol.52 , pp. 1-24
    • Zhou, W.1    Pool, V.2    Iskander, J.K.3
  • 4
    • 1942484441 scopus 로고    scopus 로고
    • Understanding vaccine safety information from the vaccine adverse event reporting system
    • Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287-94.
    • (2004) Pediatr Infect Dis J , vol.23 , pp. 287-294
    • Varricchio, F.1    Iskander, J.2    Destefano, F.3
  • 5
    • 4544251856 scopus 로고    scopus 로고
    • The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety
    • Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatr Ann 2004; 33:599-606.
    • (2004) Pediatr Ann , vol.33 , pp. 599-606
    • Iskander, J.K.1    Miller, E.R.2    Chen, R.T.3
  • 6
    • 84900427648 scopus 로고    scopus 로고
    • Postmarketing reporting of adverse experiences,21 CFR 600.80. Revised as of April 1
    • Postmarketing reporting of adverse experiences. Code of Federal Regulations. 21 CFR 600.80. Revised as of April 1, 2014.
    • (2014) Code of Federal Regulations
  • 7
    • 34447313673 scopus 로고    scopus 로고
    • Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
    • Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5675-84.
    • (2007) Vaccine , vol.25 , pp. 5675-5684
    • Ruggeberg, J.U.1    Gold, M.S.2    Bayas, J.M.3
  • 9
    • 0036300732 scopus 로고    scopus 로고
    • Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's Spontaneous Reports database
    • Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's Spontaneous Reports database. Drug Safety 2002; 25:381-92.
    • (2002) Drug Safety , vol.25 , pp. 381-392
    • Szarfman, A.1    Machado, S.G.2    O'neill, R.T.3
  • 10
    • 84935491774 scopus 로고    scopus 로고
    • US Food and Drug Administration,Accessed 4 December 2014
    • US Food and Drug Administration . Package Insert-Flublok. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM336020.pdf. Accessed 4 December 2014.
    • Package Insert-Flublok
  • 11
    • 84898047827 scopus 로고    scopus 로고
    • Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season
    • Kawai AT, Li L, Kulldorff M, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf 2014; 23:548-53.
    • (2014) Pharmacoepidemiol Drug Saf , vol.23 , pp. 548-553
    • Kawai, A.T.1    Li, L.2    Kulldorff, M.3
  • 12
    • 84887606858 scopus 로고    scopus 로고
    • Evaluating the safety of influenza vaccine using a claims-based health system
    • McCarthy NL, Gee J, Lin ND, et al. Evaluating the safety of influenza vaccine using a claims-based health system. Vaccine 2013; 31:5975-82.
    • (2013) Vaccine , vol.31 , pp. 5975-5982
    • McCarthy, N.L.1    Gee, J.2    Lin, N.D.3
  • 13
    • 73949155371 scopus 로고    scopus 로고
    • Near real-time surveillance for influenza vaccine safety: Proof-of-concept in the vaccine safety datalink project
    • Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010; 171:177-88.
    • (2010) Am J Epidemiol , vol.171 , pp. 177-188
    • Greene, S.K.1    Kulldorff, M.2    Lewis, E.M.3
  • 14
    • 84893616243 scopus 로고    scopus 로고
    • Intussusception risk after rotavirus vaccination in U.S. Infants
    • Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014; 370:503-12.
    • (2014) N Engl J Med , vol.370 , pp. 503-512
    • Yih, W.K.1    Lieu, T.A.2    Kulldorff, M.3
  • 15
    • 78149349684 scopus 로고    scopus 로고
    • US Food and Drug Administration,Accessed 4 December 2014
    • US Food and Drug Administration. FDA's Sentinel Initiative. Available at: http://www.fda.gov/Safety/FDAsSentinelinitiative/ucm2007250.htm. Accessed 4 December 2014.
    • FDA's Sentinel Initiative
  • 16
    • 84935435014 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention,Accessed 4 December 2014
    • Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. Available at: http://www.cdc.gov/ vaccinesafety/Activities/cisa.html. Accessed 4 December 2014.
    • Clinical Immunization Safety Assessment (CISA) Project


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.